The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Liebl is the Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany. His research interests include insulin therapy, pharmacoeconomics, insulin pump therapy, intraperitoneal insulin therapy, continuous glucose monitoring and other diabetes technology. He is an advisor for the German Health Authorities and Payers Organisations.
Dr. Liebl has been a board member of ‘Diabetes Technology – Insulin Pumps and Glucose Sensors’ AGDT, which is a working group of the German Diabetes Association (DDG). He is also Past-Chairman and current board member of the Diabetes Expert Commission FKDB within the DDG, and an advisor for the German Health Authorities and Payers Organisations.
Dr. Liebl has authored or co-authored more than 100 national and international publications and has delivered numerous presentations at scientific meetings all over the world.
Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Professor Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark (now part of Steno). Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years.
Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She has around 350 scientific publications and several published books and book chapters. She is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.
Danderyd University Hospital, Stockholm, Sweden
Dr Landstedt-Hallin has been working as a clinician with a focus on diabetology for the majority of her professional career. She studied medicine at the Karolinska Institute (KI), Stockholm and received her MD in 1984. While studying for a PhD at KI, she also completed residencies in both Endocrinology/Diabetology and Internal Medicine.
She worked at the Danderyd University Hospital for over thirty years, where she was an investigator in local and multicentre studies, tutored PhD students, and also held administrative positions. Her latest published research was focused on real-world data regarding insulin degludec.
In 2013 Dr Landstedt-Hallin received the award of “Clinical diabetologist of the year” from her peers in the Swedish Association for Diabetologists (SFD). She is now semi-retired but continues to work clinically 1-2 days per week at a small hospital in Norrtälje, north of Stockholm, coaching people with type 1 diabetes.
LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada
Dr Goldenberg is a consultant endocrinologist affiliated with LMC Diabetes & Endocrinology in Vaughan, Ontario. He completed his residency in Internal Medicine in 1987 and his fellowship in Endocrinology & Metabolism in 1989, both at the University of Toronto. His major areas of interest include clinical care of diabetes, obesity, dyslipidaemia and thyroid disorders.
Dr Goldenberg has been an investigator in a wide array of clinical trials in the areas of diabetes, hypertension, obesity and dyslipidaemia. He has been actively involved in Continuing Medical Education for the last 3 decades, with a strong focus on translating evidence-based medicine into practical patient care.
Dr Goldenberg was a councilor on the Diabetes Canada Clinical & Scientific Section Executive Committee from 2010 to 2016. He was also a member of the Steering Committee and an author for the 2013 CDA Clinical Practice Guidelines, lead author of the CDA March 2016 Interim Update and co-author of the November 2016 Interim Update on the Pharmacologic Management of Type 2 Diabetes. He has served on the Executive Committee and was an author for the 2018 Diabetes Canada Clinical Practice Guidelines.
Dr Goldenberg was affiliated with North York Branson/North York General Hospital from 1989 to 2020, where he served as Medical Director of the Diabetes Education Centre. He is Past-Chair of the Ontario Medical Association Section on Endocrinology & Metabolism and a previous President of the Toronto Diabetes Association.